Department of Plastic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA.
Stem Cells Transl Med. 2021 Jul;10(7):1095-1114. doi: 10.1002/sctm.20-0455. Epub 2021 Mar 16.
Acute radiation syndrome (ARS) is the radiation toxicity that can affect the hematopoietic, gastrointestinal, and nervous systems upon accidental radiation exposure within a short time. Currently, there are no effective and safe approaches to treat mass population exposure to ARS. Our study aimed to evaluate the therapeutic potential of allogeneic adipose-derived stem cells (ASCs) for total body irradiation (TBI)-induced ARS and understand the underlying mitigation mechanism. We employed 9.25 Gy TBI dose to C57BL/6 mice and studied the effect of allogeneic ASCs on mice survival and regeneration of the hematopoietic system. Our results indicate that intraperitoneal-injected ASCs migrated to the bone marrow, rescued hematopoiesis, and improved the survival of irradiated mice. Our transwell coculture results confirmed the migration of ASCs to irradiated bone marrow and rescue hematopoietic activity. Furthermore, contact coculture of ASCs improved the survival and hematopoiesis of irradiated bone marrow in vitro. Irradiation results in DNA damage, upregulation of inflammatory signals, and apoptosis in bone marrow cells, while coculture with ASCs reduces apoptosis via activation of DNA repair and the antioxidation system. Upon exposure to irradiated bone marrow cells, ASCs secrete prosurvival and hematopoietic factors, such as GM-CSF, MIP1α, MIP1β, LIX, KC, 1P-10, Rantes, IL-17, MCSF, TNFα, Eotaxin, and IP-10, which reduces oxidative stress and rescues damaged bone marrow cells from apoptosis. Our findings suggest that allogeneic ASCs therapy is effective in mitigating TBI-induced ARS in mice and may be beneficial for clinical adaptation to treat TBI-induced toxicities. Further studies will help to advocate the scale-up and adaptation of allogeneic ASCs as the radiation countermeasure.
急性辐射综合征(ARS)是指在短时间内意外辐射暴露时,可影响造血、胃肠道和神经系统的辐射毒性。目前,尚无有效且安全的方法可治疗大量人群暴露于 ARS 的情况。我们的研究旨在评估同种异体脂肪来源干细胞(ASCs)治疗全身照射(TBI)诱导的 ARS 的治疗潜力,并了解其潜在的缓解机制。我们采用 9.25Gy TBI 剂量照射 C57BL/6 小鼠,并研究了同种异体 ASC 对小鼠生存和造血系统再生的影响。结果表明,腹腔内注射的 ASC 迁移至骨髓,挽救了造血功能,并提高了照射小鼠的存活率。我们的 Transwell 共培养结果证实了 ASC 向照射骨髓的迁移和对造血活性的挽救。此外,ASC 的接触共培养改善了体外照射骨髓的存活率和造血功能。照射会导致骨髓细胞中的 DNA 损伤、炎症信号上调和细胞凋亡,而与 ASC 共培养可通过激活 DNA 修复和抗氧化系统来减少细胞凋亡。在暴露于照射的骨髓细胞时,ASC 会分泌促生存和造血因子,如 GM-CSF、MIP1α、MIP1β、LIX、KC、1P-10、Rantes、IL-17、MCSF、TNFα、Eotaxin 和 IP-10,从而减轻氧化应激并挽救受损的骨髓细胞免于凋亡。我们的研究结果表明,同种异体 ASC 治疗可有效减轻小鼠 TBI 诱导的 ARS,可能有助于临床应用以治疗 TBI 诱导的毒性。进一步的研究将有助于倡导扩大同种异体 ASC 的规模并将其作为辐射对策进行适应。